IP Group

Alphawave Semi Announces Appointment of Charlie Roach as Chief Revenue Officer

Retrieved on: 
Monday, February 12, 2024

Alphawave IP Group plc (LN: AWE, the “Company” or “Alphawave Semi”), a global leader in high-speed connectivity for the world’s technology infrastructure, has appointed Charlie Roach as Chief Revenue Officer (CRO).

Key Points: 
  • Alphawave IP Group plc (LN: AWE, the “Company” or “Alphawave Semi”), a global leader in high-speed connectivity for the world’s technology infrastructure, has appointed Charlie Roach as Chief Revenue Officer (CRO).
  • Charlie is a highly accomplished sales executive with over 20 years of experience at publicly traded companies in the semiconductor and IP communication space.
  • Charlie Roach said: “I am delighted to join the management team at Alphawave Semi.
  • Charlie comes with an impressive track record at Inphi, building strong partnerships and driving strategic wins with more than 10X revenue growth among its hyperscaler customers.

Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing

Retrieved on: 
Tuesday, January 30, 2024

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

Key Points: 
  • Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.
  • Existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group also participated.
  • Alongside the financing, Dr Rob Woodman, Partner at Panakes, joins Enterprise’s Board of Directors.
  • Dr John Ford, CEO, Enterprise Therapeutics, said: “We have made tremendous progress to date in developing novel therapeutics for patients suffering from chronic respiratory diseases.

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

Retrieved on: 
Thursday, November 30, 2023

20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.

Key Points: 
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.
  • It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma’s board of directors at the company’s 2024 Annual General Meeting.
  • “As board observes, Enrique and Elaine collectively bring decades of international pharmaceutical industry experience to Zealand Pharma,” said Martin Nicklasson, Chairman of the board of directors.
  • From January 2020 until August 2023, Enrique Conterno served as the CEO and member of the board of directors at FibroGen, Inc.

Alphawave Semi Announces Appointment of Rahul Mathur as Chief Financial Officer

Retrieved on: 
Monday, October 23, 2023

Alphawave IP Group plc (LN: AWE, the “Company” or “Alphawave Semi”), a global leader in high-speed connectivity for the World’s technology infrastructure, is pleased to announce the appointment of Rahul Mathur as Chief Financial Officer (CFO) with effect from 30 October 2023.

Key Points: 
  • Alphawave IP Group plc (LN: AWE, the “Company” or “Alphawave Semi”), a global leader in high-speed connectivity for the World’s technology infrastructure, is pleased to announce the appointment of Rahul Mathur as Chief Financial Officer (CFO) with effect from 30 October 2023.
  • Rahul served as CFO of Avantus since 2021 and as CFO and Senior Vice President Finance of Rambus from 2016 to 2021.
  • During his tenure at Rambus, Rahul was an integral part of its transformation as a product company, consistently delivering strong financial results and shareholder value.
  • Rahul Mathur said: “I am delighted to join the management team at Alphawave Semi.

Plugfest Advances Adoption of MIPI I3C Designs

Retrieved on: 
Tuesday, September 26, 2023

The publicly available, royalty-free MIPI I3C Basic is a subset of I3C that bundles the most commonly needed I3C features for developers and other standards organizations.

Key Points: 
  • The publicly available, royalty-free MIPI I3C Basic is a subset of I3C that bundles the most commonly needed I3C features for developers and other standards organizations.
  • Public versions of MIPI I3C Basic and MIPI Debug for I3C are available to download and use by developers and the open-source community.
  • “The MIPI I3C and Debug for I3C Plugfest exemplified the power of collaboration to foster seamless integration and efficiency across a breadth of applications, reinforcing the immense potential of the I3C specification.”
    The next I3C and Debug for I3C plugfest is planned for 2024 in conjunction with the 67th member meeting in Taipei, Taiwan.
  • Cadence has a strong I3C IP offering, and our participation in the plugfest facilitates the broad adoption of the MIPI I3C standard.”
    “Interoperability testing is an important step in validating new product designs," said Matthew Schnoor, debug architect with Intel Corporation.

Cadence Advances Hyperscale SoC Design with Expanded IP Portfolio for TSMC N3E Process Featuring Next-Generation 224G-LR SerDes IP

Retrieved on: 
Wednesday, September 20, 2023

Other Cadence Design IP on the advanced TSMC N3E process has demonstrated silicon success or taped out, providing mutual customers with a wide range of high-speed interface and memory IP for their most advanced designs.

Key Points: 
  • Other Cadence Design IP on the advanced TSMC N3E process has demonstrated silicon success or taped out, providing mutual customers with a wide range of high-speed interface and memory IP for their most advanced designs.
  • Addressing this surging demand, the new 224G-LR SerDes PHY IP and other leading Cadence interface IP on the TSMC N3E process usher in a new era of innovation and high-speed connectivity.
  • Our close collaboration with TSMC enables us to deliver high-quality IP designed to achieve first-pass silicon success and faster time to market.”
    The comprehensive Cadence IP portfolio on the TSMC N3E process supports the Cadence Intelligent System Design™ strategy by enabling advanced-node SoC design excellence.
  • For more information about Cadence’s next-generation 224G SerDes PHY IP and the comprehensive Cadence N3E Design IP portfolio, please visit www.cadence.com/go/N3EDIPPR .

Alphawave Semi Announces Appointment of David Reeder to Board of Directors

Retrieved on: 
Friday, September 1, 2023

Alphawave IP Group plc (LN: AWE, the “Company” or “ Alphawave Semi ”), a global leader in high-speed connectivity for the world’s technology infrastructure, is pleased to announce the appointment of David Reeder as a Non-Executive Director of the Company with effect from 1 September 2023.

Key Points: 
  • Alphawave IP Group plc (LN: AWE, the “Company” or “ Alphawave Semi ”), a global leader in high-speed connectivity for the world’s technology infrastructure, is pleased to announce the appointment of David Reeder as a Non-Executive Director of the Company with effect from 1 September 2023.
  • Following his appointment, David Reeder will become a member of the Audit Committee and the Nomination Committee.
  • David has served in senior finance and operational roles in global high technology companies including: GlobalFoundries, Texas Instruments, Broadcom, Cisco and Lexmark.
  • David Reeder said: “I am very excited to be joining the Board at Alphawave Semi, to bring my extensive experience in semiconductors to this emerging leader in the semiconductor space.

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours

Retrieved on: 
Monday, July 24, 2023

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.

Key Points: 
  • Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.
  • CB307, Crescendo’s lead proprietary programme, is now entering the cohort expansion part of the ongoing Phase 1b clinical trial.
  • The monotherapy expansion cohort is already underway in individuals with PSMA+ metastatic castration-resistant prostate cancer (mCRPC) in a last-line setting.
  • “We are delighted to have secured this additional financing which will enable us to accelerate the clinical development of CB307,” commented Theodora Harold, CEO at Crescendo Biologics.

Cadence to Acquire Rambus PHY IP Assets

Retrieved on: 
Thursday, July 20, 2023

Cadence Design Systems, Inc. (Nasdaq: CDNS) and Rambus Inc. (Nasdaq: RMBS), a premier chip and silicon IP provider making data faster and safer, today announced that they have entered into a definitive agreement for Cadence to acquire the Rambus SerDes and memory interface PHY IP business.

Key Points: 
  • Cadence Design Systems, Inc. (Nasdaq: CDNS) and Rambus Inc. (Nasdaq: RMBS), a premier chip and silicon IP provider making data faster and safer, today announced that they have entered into a definitive agreement for Cadence to acquire the Rambus SerDes and memory interface PHY IP business.
  • Rambus will retain its digital IP business, including memory and interface controllers and security IP.
  • The expected technology asset purchase also brings Cadence proven and experienced PHY engineering teams in the United States, India and Canada, further expanding Cadence’s domain-rich talent base.
  • View the full release here: https://www.businesswire.com/news/home/20230720477858/en/
    “Memory and SerDes IP design and integration continues to be integral to the design of AI, data center and hyperscale applications, CPU architectures and networking devices, and the addition of the Rambus IP and seasoned team further accelerates Cadence’s Intelligent System Design strategy, which drives design excellence,” said Boyd Phelps, senior vice president and general manager of the IP Group at Cadence.

Cadence, GlobalFoundries, Hoerzentrum Oldenburg and Leibniz University Hannover Collaborate to Advance Hearing Aid Technology

Retrieved on: 
Tuesday, July 18, 2023

The SmartHeAP SoC prototype provides hearing aid companies with all the components required to create and reprogram hearing devices that improve a wearer’s hearing experience.

Key Points: 
  • The SmartHeAP SoC prototype provides hearing aid companies with all the components required to create and reprogram hearing devices that improve a wearer’s hearing experience.
  • Cost Savings: The hearing aid software can be quickly upgraded without replacing the hardware, saving both the wearers and the hearing aid companies money.
  • “The collaboration between GF, Cadence, Hoerzentrum Oldenburg gGmbH and Leibniz University Hannover resulted in a successful hearing aid SoC that consumes significantly less power while providing hearing aid wearers with the first-of-its-kind binaural technology that transforms how they process a complete auditory scene.
  • By collaborating with Cadence, GF and Hoerzentrum Oldenburg gGmbH, we’re bringing the joy of hearing back to hearing aid wearers with this new SoC prototype.”